Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects

Justin A. Jacobson, Laura Yanoso-Scholl, David G. Reynolds, Tulin Dadali, Gino Bradica, Susan Bukata, Edward J. Puzas, Michael J. Zuscik, Randy Rosier, Regis J. O'Keefe, Edward M. Schwarz, Hani A. Awad

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

To investigate the efficacy of endocrine parathyroid hormone treatment on tissue-engineered bone regeneration, massive femoral defects in C57Bl/6 mice were reconstructed with either 100:0 or 85:15 poly-lactic acid (PLA)/beta-tricalcium phosphate (β-TCP) scaffolds (hereafter PLA or PLA/βTCP, respectively), which were fabricated with low porosity (<30%) to improve their structural rigidity. Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline. Bone regeneration was assessed longitudinally using planar X-ray and quantitative microcomputed tomography, and the reconstructed femurs were evaluated at 9 weeks either histologically or biomechanically to determine their torsional strength and rigidity. Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks and led to enhanced trabeculated bone callus formation that appeared to surround and integrate with the scaffold, thereby establishing union by bridging bone regeneration across the segmental defect in 30% of the reconstructed femurs, regardless of the scaffold type. However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds. Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union. Taken together, these observations suggest that intermittent, systemic parathyroid hormone treatment can enhance bone regeneration in scaffold-reconstructed femoral defects, which can be further enhanced by mineralized (βTCP) particles within the scaffold.

Original languageEnglish
Pages (from-to)389-398
Number of pages10
JournalTissue Engineering - Part A
Volume17
Issue number3-4
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint Dive into the research topics of 'Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects'. Together they form a unique fingerprint.

  • Cite this

    Jacobson, J. A., Yanoso-Scholl, L., Reynolds, D. G., Dadali, T., Bradica, G., Bukata, S., Puzas, E. J., Zuscik, M. J., Rosier, R., O'Keefe, R. J., Schwarz, E. M., & Awad, H. A. (2011). Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects. Tissue Engineering - Part A, 17(3-4), 389-398. https://doi.org/10.1089/ten.tea.2010.0115